We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.
Drug NameDrug | DiseaseDis | IND EnablingIND | Phase 1/2Ph 1/2 | Phase 3Ph 3 | CollaboratorCollab |
|---|---|---|---|---|---|
ZN-c5: Oral SERD Monotherapy | ZN-c5: Oral SERD |  | |||
ZN-c5: Oral SERD Combinations | ZN-c5: Oral SERD |  | |||
ZN-c3: WEE1 Solid Tumors | ZN-c3: WEE1 Monotherapy | ZN-c3: WEE1 ZN-c3: WEE1 | | ||
ZN-c3: WEE1 Combinations | ZN-c3: WEE1 | ||||
ZN-d5: BCL-2 AML or B-cell Lymphoma | ZN-d5: BCL-2 Monotherapy | ZN-d5: BCL-2 ZN-d5: BCL-2 | | ||
ZN-d5: BCL-2 Breast Cancer | ZN-d5: BCL-2 Combination with ZN-c5 | ZN-d5: BCL-2 ZN-d5: BCL-2 | |||
ZN-e4: EGFR NSCLC | ZN-e4: EGFR | ZN-e4: EGFR ZN-e4: EGFR |  | ||